Ligand Pharmaceuticals, Inc. (LGND)
280.18
-6.11
(-2.13%)
USD |
NASDAQ |
Aug 24, 16:00
280.04
-0.14
(-0.05%)
After-Hours: 20:00
Ligand Pharmaceuticals Net Income (Quarterly) : 48.51M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 48.51M |
| March 31, 2026 | -13.34M |
| December 31, 2025 | 44.78M |
| September 30, 2025 | 117.27M |
| June 30, 2025 | 4.847M |
| March 31, 2025 | -42.45M |
| December 31, 2024 | -31.09M |
| September 30, 2024 | -7.172M |
| June 30, 2024 | -51.91M |
| March 31, 2024 | 86.14M |
| December 31, 2023 | 18.19M |
| September 30, 2023 | -10.27M |
| June 30, 2023 | 2.29M |
| March 31, 2023 | 43.61M |
| December 31, 2022 | -14.53M |
| September 30, 2022 | 9.645M |
| June 30, 2022 | 12.60M |
| March 31, 2022 | -12.93M |
| December 31, 2021 | -3.194M |
| September 30, 2021 | 13.72M |
| June 30, 2021 | 30.72M |
| March 31, 2021 | 18.11M |
| December 31, 2020 | 5.761M |
| September 30, 2020 | -6.701M |
| June 30, 2020 | 22.09M |
| Date | Value |
|---|---|
| March 31, 2020 | -24.13M |
| December 31, 2019 | -7.365M |
| September 30, 2019 | -15.25M |
| June 30, 2019 | -14.42M |
| March 31, 2019 | 666.34M |
| December 31, 2018 | -42.48M |
| September 30, 2018 | 67.36M |
| June 30, 2018 | 73.16M |
| March 31, 2018 | 45.28M |
| December 31, 2017 | -7.01M |
| September 30, 2017 | 8.426M |
| June 30, 2017 | 6.058M |
| March 31, 2017 | 5.079M |
| December 31, 2016 | -3.126M |
| September 30, 2016 | 1.051M |
| June 30, 2016 | -6.17M |
| March 31, 2016 | 5.877M |
| December 31, 2015 | 6.341M |
| September 30, 2015 | 199.16M |
| June 30, 2015 | 22.03M |
| March 31, 2015 | -0.089M |
| December 31, 2014 | 6.733M |
| September 30, 2014 | 0.777M |
| June 30, 2014 | 1.288M |
| March 31, 2014 | 2.097M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
| Merck & Co., Inc. | -1.337B |
| Zevra Therapeutics, Inc. | 8.393M |
| Liquidia Corp. | 74.72M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 63.69M |
| Total Expenses (Quarterly) | 15.18M |
| EPS Diluted (Quarterly) | 2.221 |
| Enterprise Value | 5.355B |
| Gross Profit Margin (Quarterly) | 82.24% |
| Profit Margin (Quarterly) | 76.16% |
| Earnings Yield | 3.34% |
| Operating Earnings Yield | 1.71% |
| Normalized Earnings Yield | 2.512 |